Understanding CYP3A4 and P‐gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib

• Main Authors: Christine Bowman (Author), Michael Dolton (Author), Fang Ma (Author), Sravanthi Cheeti (Author), Denison Kuruvilla (Author), Rucha Sane (Author), Nastya Kassir (Author), Yuan Chen (Author)
• Format: Book
• Published: Wiley, 2024-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Pralsetinib, a potent and selective inhibitor of oncogenic RET fusion and RET mutant proteins, is a substrate of the drug metabolizing enzyme CYP3A4 and a substrate of the efflux transporter P‐gp based on in vitro data. Therefore, its pharmacokinetics (PKs) may be affected by co‐administrat...